

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Ergotamine tartrate/anhydrous caffeine/isopropylantipyrine

March 17, 2026

Therapeutic category

Antipyretics, analgesics and anti-inflammatory agents

Non-proprietary name

Ergotamine tartrate/anhydrous caffeine/isopropylantipyrine

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision												
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: HIV protease inhibitors (preparations containing ritonavir, fosamprenavir, atazanavir, darunavir), efavirenz, preparations containing cobicistat, macrolide antibiotics (erythromycin, josamycin, clarithromycin, roxithromycin), azole antifungal agents (itraconazole, miconazole, fluconazole, fosfluconazole, voriconazole, posaconazole), letermovir, ensitrelvir, lenacapavir, lonafarnib, 5-HT_{1B/1D} receptor agonists (sumatriptan, zolmitriptan, eletriptan, rizatriptan, naratriptan), ergot alkaloids (ergometrine, methylergometrine)</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table border="1" data-bbox="241 1066 1102 1428"> <thead> <tr> <th data-bbox="241 1066 582 1141">Drugs</th> <th data-bbox="586 1066 824 1141">Signs, symptoms, and treatment</th> <th data-bbox="828 1066 1102 1141">Mechanism/risk factors</th> </tr> </thead> <tbody> <tr> <td data-bbox="241 1144 582 1428">HIV protease inhibitors Preparations containing ritonavir, fosamprenavir, atazanavir, darunavir Efavirenz</td> <td data-bbox="586 1144 824 1428">The blood concentration of ergotamine may increase, which may cause serious adverse reactions such as angiospasm.</td> <td data-bbox="828 1144 1102 1428">The metabolism of ergotamine is suppressed due to CYP3A4 inhibition by these drugs.</td> </tr> </tbody> </table>	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	HIV protease inhibitors Preparations containing ritonavir, fosamprenavir, atazanavir, darunavir Efavirenz	The blood concentration of ergotamine may increase, which may cause serious adverse reactions such as angiospasm.	The metabolism of ergotamine is suppressed due to CYP3A4 inhibition by these drugs.	<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: HIV protease inhibitors (preparations containing ritonavir, fosamprenavir, atazanavir, darunavir), efavirenz, preparations containing cobicistat, macrolide antibiotics (erythromycin, josamycin, clarithromycin, roxithromycin), azole antifungal agents (itraconazole, miconazole, fluconazole, fosfluconazole, voriconazole, posaconazole), letermovir, ensitrelvir, lenacapavir, lonafarnib, <u>ceritinib</u>, 5-HT_{1B/1D} receptor agonists (sumatriptan, zolmitriptan, eletriptan, rizatriptan, naratriptan), ergot alkaloids (ergometrine, methylergometrine)</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table border="1" data-bbox="1137 1066 1998 1428"> <thead> <tr> <th data-bbox="1137 1066 1473 1141">Drugs</th> <th data-bbox="1478 1066 1715 1141">Signs, symptoms, and treatment</th> <th data-bbox="1720 1066 1998 1141">Mechanism/risk factors</th> </tr> </thead> <tbody> <tr> <td data-bbox="1137 1144 1473 1428">HIV protease inhibitors Preparations containing ritonavir, fosamprenavir, atazanavir, darunavir Efavirenz</td> <td data-bbox="1478 1144 1715 1428">The blood concentration of ergotamine may increase, which may cause serious adverse reactions such as angiospasm.</td> <td data-bbox="1720 1144 1998 1428">The metabolism of ergotamine is suppressed due to CYP3A4 inhibition by these drugs.</td> </tr> </tbody> </table>	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	HIV protease inhibitors Preparations containing ritonavir, fosamprenavir, atazanavir, darunavir Efavirenz	The blood concentration of ergotamine may increase, which may cause serious adverse reactions such as angiospasm.	The metabolism of ergotamine is suppressed due to CYP3A4 inhibition by these drugs.
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors											
HIV protease inhibitors Preparations containing ritonavir, fosamprenavir, atazanavir, darunavir Efavirenz	The blood concentration of ergotamine may increase, which may cause serious adverse reactions such as angiospasm.	The metabolism of ergotamine is suppressed due to CYP3A4 inhibition by these drugs.											
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors											
HIV protease inhibitors Preparations containing ritonavir, fosamprenavir, atazanavir, darunavir Efavirenz	The blood concentration of ergotamine may increase, which may cause serious adverse reactions such as angiospasm.	The metabolism of ergotamine is suppressed due to CYP3A4 inhibition by these drugs.											

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Preparations containing cobicistat Macrolide antibiotics Erythromycin, josamycin, clarithromycin, roxithromycin Azole antifungal agents Itraconazole, miconazole, fluconazole, fosfluconazole, voriconazole, posaconazole Letermovir Ensitrelvir Lenacapavir Lonafarnib			Preparations containing cobicistat Macrolide antibiotics Erythromycin, josamycin, clarithromycin, roxithromycin Azole antifungal agents Itraconazole, miconazole, fluconazole, fosfluconazole, voriconazole, posaconazole Letermovir Ensitrelvir Lenacapavi Lonafarnib <u>Ceritinib</u>		
---	--	--	--	--	--